Meeting
2022 ASCO Genitourinary Cancers Symposium
A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).
Authors
Thomas Powles
Barts Cancer Centre, Queen Mary University of London, London, United Kingdom
Thomas Powles , Alexandra Drakaki , Jeremy Yuen-Chun Teoh , Enrique Grande , Mario Fontes-Sousa , Camillo Porta , Esther Wu , Erik T. Goluboff , Svetlana Ho , Stephan Hois , Ashok Kumar Gupta , James W.F. Catto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04960709
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS579)
DOI
10.1200/JCO.2022.40.6_suppl.TPS579
Abstract #
TPS579
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt D. Galsky
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
First Author: Petros Grivas
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
First Author: Thomas Powles
Poster
2019 ASCO Annual Meeting
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
First Author: Thomas Powles